AstraZeneca’s Nexium, GSK’s Zofran Among Latest Victims Of China Price Cuts; NDRC Plans Further Pricing Reforms To Encourage Innovation

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.